ICCVS is a Centre of Excellence established in 2017 as part of the IBA FNP programme at the University of Gdańsk. Since then, we have developed an algorithm to identify T cells that selectively recognize and destroy autologous cancer cells. In parallel, we have developed a method for identifying and quantifying tumor-specific antigens presented by its class I MHC molecules (neoantigens). Therefore, as part of the current project, we want to use this knowledge and know-how to develop a comprehensive cancer therapy that will be transferred to the clinical trial phase and open new research paths in oncology. To achieve this goal, the current project consists of the following two parts, which will be developed in parallel: 1) Clinical trial and 2) Research and development activities focused on improving the approach tested in the clinical trial.In the SWIFT project, we plan to direct R&D activities in the following directions: 1). Identification of neoantigens presented by Class I and Class II tumor MHC molecules and isolation of T-cell clones that recognize them (groups involved: Clinical Peptdomics, Cancer Immunology, Structural Peptdomics, Immunological Memory & Cell Reprogramming)2). Determination of receptor-ligand pairs responsible for the binding of neoplastic extracellular vesicles (EVs) to T cells (groups involved: Clinical Peptdomics, Structural Proteomics and Cancer Immunology) 3). Develop strategies to prevent reprogramming of T cells by neoplastic extracellular follicles (groups involved: Immunological Memory & Cell Reprogramming, Structural Proteomics and Cancer Immunology)4). Modification of the tumor microenvironment with reprogrammed autologous monocytes (involved groups: Immunological Memory & Cell Reprogramming, Cancer Immunology, Structural Proteomics and Clinical Peptdomics).